Mira Pharmaceuticals received a notice from Nasdaq indicating it no longer meets the minimum bid price requirement of $1 per share due to its closing stock price for 30 consecutive business days ending July 24, 2026. The company has an 180-day compliance period until January 25, 2027, during which the stock must close at or above $1 for ten consecutive trading days. Failure to comply may result in delisting, though the company may seek a second extension and consider a reverse stock split as a remediation option. Mira Pharmaceuticals operates in the pharmaceutical industry.

MIRA Pharmaceuticals, Inc. announced positive preclinical study results for MIRA-55, its non-opioid oral drug candidate for chronic inflammatory pain. The optimized oral formulation demonstrated favorable oral bioavailability, sustained systemic exposure, and reproducible distribution into brain and liver tissue. MIRA Pharmaceuticals, Inc. is a pharmaceutical company developing non-opioid pain management therapies.

MIRA Pharmaceuticals, Inc. announced on July 6, 2026, positive preclinical study results for the optimized oral formulation of SKNY-1, an oral drug candidate for obesity and addiction-related disorders. The studies demonstrated favorable oral bioavailability, systemic exposure, and robust brain penetration. MIRA Pharmaceuticals, Inc. is a biopharmaceutical company developing drug candidates for obesity and addiction-related disorders.